HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/adlai-nortye-ltd" target="_blank" data-smartkarma-citation="entities:34049:1" rel="noopener">Adlai Nortye (ADN HK)</a> is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.</li>
<li> This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.</li>
<li>Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. </li>
</ul>



Adlai Nortye (ADN HK) is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies for patients across various stages of tumors.
 This article mainly analyzed the clinical-stage drug candidates in the pipeline, including AN2025, AN0025, AN1004, AN4005 and others.
Due to the concerns on early-stage pipeline, commercialization prospect, policy risks and the market's attitude towards license-in mode, we are conservative about the outlook of the Company at the current stage. 


Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

This article mainly analyzed Adlai Nortye in terms of its important clinical-stage drug candidates, the competition pattern, commercialization...

Xinyao (Criss) Wang